Literature DB >> 30460419

Serum histamine and acetylcholine variations as new noninvasive biochemical markers in staging of experimental hepatocellular carcinoma.

Nabil M Abdel-Hamid1,2, Amer Hasan Abdullah3.   

Abstract

Angiogenesis is a major prerequisite for hepatocellular carcinoma (HCC) development and progression. The present study aims to assess the potential role of two endogenous regulators of angiogenesis histamine (His) and acetylcholine (Ach), as possible biochemical markers for staging of HCC. Five groups of rats were used in this study: a control healthy group (I), another 4 intoxicated groups used for the induction of HCC with a high dose of diethyl nitrosamine (DENA, 200 mg/kg, single I.P. dose), (II, III, IV, and V). Groups II, III, IV, and V were killed following 8, 16, 24, and 32 weeks after DENA injection, respectively. Serum level of His and Ach was estimated using high-performance liquid chromatography technique coupled with diode array detector (HPLC-DAD), and alpha-fetoprotein (AFP) was measured using ELISA technique along with liver histological examination for all groups. Progression of HCC was estimated by histopathological examination. The results exhibited prominent increase in serum His and Ach levels during the early stages of HCC in group II, III in comparison with the control, and then His serum level declined to the normal level during the last stage of HCC development (group V).However, Ach elevation continued. AFP serum level showed marked increase, till 32 weeks after hepatocarcinogenesis. The decreased histamine level, combined to elevated AFP, indicates an early stage, while continued elevation of Ach with decreased His levels indicates a later stage of HCC. The combination of these two neurotransmitters to AFP may contribute to a noninvasive biochemical staging for HCC.

Entities:  

Keywords:  AFP; Acetylcholine; Hepatocellular carcinoma; Histamine; Staging

Mesh:

Substances:

Year:  2018        PMID: 30460419     DOI: 10.1007/s10238-018-0537-y

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  44 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Suppression of melanoma cell proliferation by histidine decarboxylase specific antisense oligonucleotides.

Authors:  H Hegyesi; B Somlai; V L Varga; G Toth; P Kovacs; E L Molnar; V Laszlo; S Karpati; E Rivera; A Falus; Z Darvas
Journal:  J Invest Dermatol       Date:  2001-07       Impact factor: 8.551

3.  The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients.

Authors:  M M Hassan; A S Zaghloul; H B El-Serag; O Soliman; Y Z Patt; C L Chappell; R P Beasley; L Y Hwang
Journal:  J Clin Gastroenterol       Date:  2001-08       Impact factor: 3.062

4.  Expression of histidine decarboxylase and synthesis of histamine by human small cell lung carcinoma.

Authors:  Lothar Graff; Mónica Frungieri; Robert Zanner; Agnes Pohlinger; Christian Prinz; Manfred Gratzl
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 5.  Histamine, polyamines, and cancer.

Authors:  M A Medina; A R Quesada; I Núñez de Castro; F Sánchez-Jiménez
Journal:  Biochem Pharmacol       Date:  1999-06-15       Impact factor: 5.858

6.  A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades.

Authors:  Yasuhito Tanaka; Kousuke Hanada; Masashi Mizokami; Anthony E T Yeo; J Wai-Kuo Shih; Takashi Gojobori; Harvey J Alter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

7.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

8.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

9.  Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence.

Authors:  F Abdel-Aziz; M Habib; M K Mohamed; M Abdel-Hamid; F Gamil; S Madkour; N N Mikhail; D Thomas; A D Fix; G T Strickland; W Anwar; I Sallam
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

Review 10.  Epidemiology of hepatocellular carcinoma.

Authors:  M C Yu; J M Yuan; S Govindarajan; R K Ross
Journal:  Can J Gastroenterol       Date:  2000-09       Impact factor: 3.522

View more
  4 in total

Review 1.  Muscarinic Receptors Associated with Cancer.

Authors:  Gloria M Calaf; Leodan A Crispin; Juan P Muñoz; Francisco Aguayo; Tammy C Bleak
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

2.  Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling.

Authors:  Lindsey Kennedy; Vik Meadows; Jennifer Demieville; Laura Hargrove; Shohaib Virani; Shannon Glaser; Tianhao Zhou; Evan Rinehart; Victoria Jaeger; Konstantina Kyritsi; Linh Pham; Gianfranco Alpini; Heather Francis
Journal:  Lab Invest       Date:  2020-02-13       Impact factor: 5.662

3.  Histamine H3 Receptor Promotes Cell Survival via Regulating PKA/CREB/CDKN1A Signal Pathway in Hepatocellular Carcinoma.

Authors:  Chunle Zhang; Yang Yu; Liang Ma; Ping Fu
Journal:  Onco Targets Ther       Date:  2020-05-04       Impact factor: 4.147

4.  REC8 promotes tumor migration, invasion and angiogenesis by targeting the PKA pathway in hepatocellular carcinoma.

Authors:  Jing Han; Yun Bai; Jia Wang; Xiao-Li Xie; Ai-di Li; Qian Ding; Zi-Jin Cui; Jie Yin; Xiao-Yu Jiang; Hui-Qing Jiang
Journal:  Clin Exp Med       Date:  2021-03-07       Impact factor: 3.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.